Active ingredientMavacamtenCat. No. P-M012-001CAS 1642288-47-8Family · Pharmaceutical analytical standards
Mavacamten
A cardiac myosin inhibitor, the first in its class, approved in the United States in 2022 and in Europe in 2023 for symptomatic obstructive hypertrophic cardiomyopathy. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?It acts directly on the 'motor' of contraction: it shifts part of the myosin molecules into a low-energy resting state, reducing excess bonds with actin.
Go to the active ingredient →Active ingredientMavacamtenCat. No. P-M012-001CAS 1642288-47-8
NitrosamineN1-Nitroso MavacamtenCat. No. P-M012-002
Impurity(R)-MavacamtenCat. No. P-M012-003CAS 1642288-64-9
ImpurityMavacamten Impurity 1Cat. No. P-M012-004CAS 30221-94-4
ImpurityMavacamten Impurity 2Cat. No. P-M012-005CAS 81250-37-5
ImpurityDiethyl 2,4,6-trihydroxyisophthalateCat. No. P-M012-006CAS 10135-18-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.